Prabhudas Lilladher's research report on Fortis Healthcare
Fortis Healthcare (FORH) Q1FY25 EBITDA was largely in line with our estimates. Though hospital margins saw 170 bps YoY improvement in FY24, we see further margin improvement in hospital segment aided by 1) improving case and payor mix 2) cost rationalization initiatives and 3) new brownfield bed addition. Our FY25E and FY26E hospital EBITDA largely remains unchanged.
Outlook
We expect 21% EBITDA CAGR over FY24-26E. At CMP, stock is trading at 22x EV/EBITDA on FY26E, adjusted for Agilus stake. Maintain ‘Buy’ rating with TP of Rs 515/share; valuing hospital segment at 23x and diagnostic at 18x EV/EBITDA on FY26E. Resolution of legal issues and profitability improvement in Agilus will be key for re-rating. Fortis will invest Rs18bn in diagnostic business which will increase its stake to 88%. Given growth in diagnostic segment have been muted; investments will see RoCE dilutive in near term. However; Agilus stake purchase at 22x EV/EBITDA on trailing basis is at much discount to peers.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
